Star Therapeutics raised $125 million to develop antibody-based therapeutics for bleeding disorders and other underserved conditions, using proprietary platforms to provide targeted, patient-centered treatments.
Star Therapeutics raised $125 million to develop antibody-based therapeutics for bleeding disorders and other underserved conditions, using proprietary platforms to provide targeted, patient-centered treatments.
